Upgrade to SI Premium - Free Trial

Aerie Pharma (AERI) Commences Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan

November 16, 2017 4:16 PM
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) today announced the commencement of patient dosing in its Phase 2 clinical trial designed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles